Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Geomerics IP Validation

27 Jul 2006 07:00

Angle PLC27 July 2006 For Immediate Release 27 July 2006 ANGLE plc ("ANGLE") Core intellectual property validation: Geomerics Ltd ("Geomerics") ANGLE, the venture management and consulting company specialising in thecommercialisation of technology, is pleased to announce the validation ofProgeny(R) company Geomerics' core intellectual property through demonstrationof a revolutionary new computer graphics technology. Geomerics has unveiled technology that allows real-time radiosity in computergames utilising commodity graphics processing hardware. Radiosity, the processof fully modelling the subtle effects arising from the inter-reflections oflight between surfaces, dominates many real-world situations. Until now, sucheffects were considered beyond the reach of real-time techniques producingnoticeably 'unrealistic' lighting in computer games. Geomerics' breakthrough dynamic radiosity solution enables the full range oflighting effects, including inter-reflections, to be updated in real-time,providing significantly greater realism and impact. Geomerics has applied itscore intellectual property, based around geometric algebra, to produce thisradical new radiosity solution. The solution allows for fully dynamic lighting,including point spot-lights, area lights, texture-based lighting, glowingobjects and the projection of video onto geometry, all on common video hardware. Geomerics provided the first live demonstration of the technology at the DevelopConference in Brighton on 13 July. ANGLE is pleased to announce that subsequentindustry response to the technology was considerable, with over fifty commercialenquiries including many leading games developers. ANGLE believes that thisdemonstration is a validation of the power of Geomerics' core intellectualproperty and looks forward to both further applications and imminent commercialvalidation. Further details, including screenshots, movies, and previews of other Geomericssolutions can be found at www.geomerics.com Chris Doran, CEO and founder of Geomerics commented, "This revolutionarylighting technique is a demonstration of the potential of Geomerics' technologyand our unique approach to games middleware and technology licensing. Geometricalgebra provides opportunities for totally new solutions in a huge range ofgames problems, from lighting to physics and beyond." Andrew Newland, CEO of ANGLE, commented, "We are excited to view the validationof Geomerics' core intellectual property. The company has made good progress todate and we look forward to further applications of the core intellectualproperty in the near future." Geomerics, founded by ANGLE in 2005, is commercialising geometric algebratechnology developed at the University of Cambridge, UK, and in the USA. Thistechnology has applicability in the computer games industry, where it enablesfilm-quality visuals to be generated in real-time; in electromagnetic modelling,where a step-change in accuracy and speed can be seen; and in a wide selectionof other industries, to be announced by the company in due course. Geomerics is an ANGLE Progeny(R) Company. For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures GeomericsAlison Beasley of Lincoln Beasley PR +44 1608 645756 Buchanan CommunicationsRichard Darby, Amy Rajendran +44 207 466 5000 Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.